Not many biotech specs ever make it to the stage where they are bought out like this. I had hoped for a bit more, but the immunotherapy field is now becoming so crowded I was starting to think that Viralytics were going to be left out in the cold. Personally happy to take the money and invest in other opportunities. Still wouldn't mind a counter offer, but seriously don't think it will happen.
Not many biotech specs ever make it to the stage where they are...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
